ArticleCardiovascular and interventional radiology2025
Risk Factors for Residual Unablated Tumour Following CT-Guided Percutaneous Renal Cryoablation: Lessons from the EuRECA Registry.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Percutaneous Cryoablation of Clinical T1b Renal Tumors: A Tertiary Cancer Center Experience.Cardiovascular and interventional radiology · 2026Observational
- Image-guided percutaneous ablation techniques for the treatment of renal cell carcinoma: a primer for radiologists.Abdominal radiology (New York) · 2026Review
- Adjunctive Techniques for Optimizing Percutaneous CT-Guided Cryoablation of Renal Tumours.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess tumour factors that reduce primary technical efficacy (PTE) from CT-guided renal cryoablation.
methodsPatients were taken from the EuRECA registry between December 2014 and November 2020. To focus on tumour factors rather than individual technique, this study was limited to cases using CT and excluded procedures using cone beam, US, MRI, or laparoscopy. PTE was assessed per tumour and defined as complete ablation of the target on enhanced CT or MRI by 90 days. Residual unablated tumour (RUT) was defined as focal persistent tumour enhancement within 90 days.
resultsA total of 1,424 tumours from 11 different centres were eligible; 38 episodes of RUT were detected giving an overall PTE of 97.3%. The factors most likely to be associated with RUT were as follows and persisted in multivariate logistic regression. Tumour contact with a central artery or vein; increased OR of 5.29 (CI 2.59-10.81 p < 0.001), PTE was 89.8% in this group. Tumours size; T1b vs T1a increased OR of 2.31 (CI 1.10-4.87 p = 0.0276), T1b PTE was 94.1% vs T1a PTE 97.9%. Close proximity to the collecting system (< 4 mm) was significant at univariate logistic regression (OR 2.87, P = 0.028), as was a RENAL complexity score of 10 or above (OR 2.71, p = 0.0147), but neither was significant in the multivariate analysis.
conclusionsOverall, CT-guided percutaneous renal cryoablation has a high PTE at 97.3%. In this analysis, the most significant risk factor for RUT is central renal vessel contact. T1b tumours are also noted to have an increased risk of RUT compared to T1a.
Indexed as
Identifiers
39821654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.